Scarica l'app Stockscreener
57.68
1.67%
0.95
Dopo l'orario di chiusura:
57.68
Precedente Chiudi:
$56.73
Aprire:
$56.19
Volume 24 ore:
611.62K
Relative Volume:
1.12
Capitalizzazione di mercato:
$1.66B
Reddito:
$234.60M
Utile/perdita netta:
$-13.23M
Rapporto P/E:
-110.80
EPS:
-0.5206
Flusso di cassa netto:
$19.61M
1 W Prestazione:
-11.25%
1M Prestazione:
+5.04%
6M Prestazione:
+84.05%
1 anno Prestazione:
+204.06%
Intervallo 1D:
$56.03
$60.14
Intervallo di 1 settimana:
$54.23
$66.28
Portata 52W:
$15.40
$68.39
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
57.68 | 1.66B | 234.60M | -13.23M | 19.61M | -0.5206 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio, Inc. Common Stock When Issued (ANABV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Assessing AnaptysBio (ANAB) Valuation After New US$100 Million Buyback And Cancelled Equity Offerings - Yahoo Finance
J.P. Morgan Maintains AnaptysBio(ANAB.US) With Buy Rating, Announces Target Price $69 - moomoo.com
Director Susannah Gray at AnaptysBio (ANAB) submits initial Form 3 - Stock Titan
ANAB Technical Analysis & Stock Price Forecast - Intellectia AI
Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback - msn.com
ANABV|AnaptysBio Ord Shs|| - TradingKey
First Tracks Biotherapeutics to be spun off from AnaptysBio, Nasdaq trading set for April 20 - Investing.com
Insider Selling: AnaptysBio (NASDAQ:ANAB) Director Sells 20,645 Shares of Stock - MarketBeat
Aug Highlights: Can AnaptysBio Inc grow without external funding2026 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
AnaptysBio Insider Sold Shares Worth $1,158,451, According to a Recent SEC Filing - MarketScreener
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Director John Schmid Sells 20,645 Shares of AnaptysBio Inc (ANAB) - GuruFocus
Anaptysbio director Schmid sells $1.16 million in stock By Investing.com - Investing.com Canada
[Form 4] ANAPTYSBIO, INC Insider Trading Activity - Stock Titan
AnaptysBio Director Sold Shares Worth Over $1.1M - TradingView
Aug Volume: Is AnaptysBio Inc stock a good dividend stock2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Wedbush Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $75 - Moomoo
ANAB: Piper Sandler Raises Price Target to $95.00, Maintains Ove - GuruFocus
ANAB: Piper Sandler Raises Price Target to $95.00, Maintains Overweight Rating | ANAB Stock News - GuruFocus
Piper Sandler Raises AnaptysBio (NASDAQ:ANAB) Price Target to $95.00 - MarketBeat
Piper Sandler raises AnaptysBio stock price target to $95 from $67 - Investing.com Canada
H.C. Wainwright reiterates Buy on AnaptysBio stock after spinoff news By Investing.com - Investing.com Canada
HC Wainwright & Co. Reiterates Buy Rating on AnaptysBio (ANAB) | - GuruFocus
[144] ANAPTYSBIO, INC SEC Filing - Stock Titan
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Raises Target Price to $66 - Moomoo
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - MarketScreener
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright - MarketBeat
AnaptysBio Insider Sold Shares Worth $1,089,199, According to a Recent SEC Filing - MarketScreener
AnaptysBio Spin Off Reshapes Risk Profile With New Royalty Focus - Sahm
AnaptysBio (ANAB) price target increased by 21.16% to 79.82 - msn.com
Biotech Startup First Tracks Secures $145M in Private Funding - National Today
(ANAB) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
AnaptysBio authorizes $100M stock buyback, plans spin-off By Investing.com - Investing.com Australia
AnaptysBio sets April 20 spin-off date for First Tracks Bio - Investing.com Australia
AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 17,679 Shares - MarketBeat
AnaptysBio Authorizes $100 Billion Buyback Plan - National Today
AnaptysBio (NASDAQ:ANAB) Board of Directors Authorizes Share Buyback Plan - MarketBeat
Anaptysbio CEO Faga sells $1.1 million in shares By Investing.com - Investing.com Australia
AnaptysBio spinoff First Tracks Bio raises $80M in placement By Investing.com - Investing.com India
AnaptysBio (NASDAQ: ANAB) CEO gets PSU grant and sells shares for tax - Stock Titan
Anaptysbio CEO Faga sells $1.1 million in shares - Investing.com
Anaptysbio, Inc. Appoints Susannah Gray to the Board of Directors - marketscreener.com
Anaptysbio, Inc. Announces Managing the Financial Collaborations for Jemperli with Gsk and Imsidolimab with Vanda - MarketScreener
AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million Shares - Moomoo
AnaptysBio Advances First Tracks Spin-Off and Governance Changes - TipRanks
Sector Update: Health Care Stocks Retreat Friday Afternoon - Moomoo
AnaptysBio (NASDAQ:ANAB) Shares Down 10.3%Time to Sell? - MarketBeat
AnaptysBio Announces $100 Million Stock Repurchase Program and Updates on Clinical Development Progress - geneonline.com
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):